Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy (Q59489249)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Schjoedt KJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Rossing K

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Juhl TR

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Boomsma F

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Rossing P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Parving HH

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

language of work or name

English

0 references

publication date

14 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

536-542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16775595%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001580

30 January 2020

exact match

0 references

cites work

Prognosis in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Remission of nephrotic-range albuminuria in type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Efficacy of low-dose spironolactone in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Initiation and progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Understanding controlled trials. Crossover trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Selection of Routine Method for Determination of Glomerular Filtration Rate in Adult Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

A Simple Method for the Determination of Glomerular Filtration Rate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021

Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001580

7 January 2021